Results 51 to 60 of about 63,671 (294)

Azathioprine: its uses in dermatology

Anais Brasileiros de Dermatologia, 2020
This is a narrative review of azathioprine. This medication is immunomodulatory and immunosuppressive, and it has been used widely through different medical specialties to modify disease. It has been proven useful for several dermatoses and it has encountered success when used as an off-label indication for other dermatologic diseases. Its mechanism of
Sonia Chavez-Alvarez, Maira Herz-Ruelas, Alejandra Villarreal-Martinez, Jorge Ocampo-Candiani, Rubicela Garza-Garza, Minerva Gomez-Flores   +5 more
openaire   +7 more sources

Phagocytosis and Epithelial Cell Invasion by Crohn’s Disease-Associated Adherent-Invasive Escherichia coli Are Inhibited by the Anti-inflammatory Drug 6-Mercaptopurine

Frontiers in Microbiology, 2018
Adherent-invasive Escherichia coli (AIEC) strains are overrepresented in the dysbiotic microbiota of Crohn’s disease (CD) patients, and contribute to the onset of the chronic inflammation typical of the disease.
Federica Migliore, Raffaella Macchi, Paolo Landini, Moira Paroni   +3 more
doaj   +1 more source

Azathioprine induced acute sialadenitis: A case report

Clinical Case Reports, 2023
Key clinical message Patients presenting with acute sialadenitis need careful review of their medications. Azathioprine is one of such drugs, which can rarely induce acute sialadenitis.
Priyanka Moovara Cackamvalli, Faten Mohammed Abdullah Al Bakri, Izzat Ali M. Khanjar   +2 more
doaj   +1 more source

Pediatric IBD patients show medication and disease activity dependent changes in NK cell and CD4 memory T cell populations

Frontiers in Pediatrics, 2023
ObjectivesCD4+ memory T cells facilitate long-termed adaptive immune responses while NK cells are predominately rapid effector cells with significant functions for both intestinal homeostasis and inflammation.
Angeliki Pappa, Julia Mührer, Patricia Gast, Sudheendra Hebbar Subramanyam, Kim Ohl, Moritz Muschaweck, Norbert Wagner, Tobias Wenzl, Klaus Tenbrock   +8 more
doaj   +1 more source

Azathioprine, cyclophosphamide and chlorambucil

Baillière's Clinical Rheumatology, 1990
Immunosuppressive agents serve a major role in the management of once-fatal conditions such as the systemic necrotizing vasculitides, but they are also being used in more common, chronic inflammatory disorders such as rheumatoid arthritis. The drugs are all capable of reducing cell division but they differ in their modes of action.
Luqmani, R, Palmer, R, Bacon, P
openaire   +3 more sources

Role of STING Deficiency in Amelioration of Mouse Models of Lupus and Atherosclerosis

Arthritis &Rheumatology, EarlyView.
Objective Systemic lupus erythematosus (SLE) is a systemic autoimmune syndrome characterized by autoreactive responses to nucleic acids, dysregulation of the type I interferon (IFN‐I) pathway, and accelerated atherosclerosis. The stimulator of IFN genes (STING), a cytosolic DNA sensor, has pathogenic implications in various inflammatory diseases ...
Yudong Liu, Carmelo Carmona‐Rivera, Nickie L. Seto, Christopher B. Oliveira, Eduardo Patino‐Martinez, Yvonne Baumer, Tiffany M. Powell‐Wiley, Nehal Mehta, Sarfaraz Hasni, Xuan Zhang, Mariana J. Kaplan   +10 more
wiley   +1 more source

Atopic Dermatitis: Drug Delivery (Management) and Approaches (Strategies) in Perspective

Annals of the National Academy of Medical Sciences (India), 2018
Age-related cutaneous manifestations are definitive pointer to the diagnosis of atopic dermatitis, the confirmation of which is solicited by 3 major and 3 minor criteria. Its unpredictable course is punctuated by exacerbations and remissions.
Virendra N. Sehgal
doaj   +1 more source

Efficacy and Safety of Subcutaneous Abatacept Plus Standard Treatment for Active Idiopathic Inflammatory Myopathy: Phase 3 Randomized Controlled Trial

Arthritis &Rheumatology, EarlyView.
Objective Our objective was to evaluate the efficacy and safety of subcutaneous (SC) abatacept and standard of care (SOC) for the treatment of idiopathic inflammatory myopathy (IIM) over 52 weeks. Methods In this randomized, double‐blind, placebo‐controlled phase III trial, patients with treatment‐refractory IIM received SC abatacept (at 125 mg weekly)
Rohit Aggarwal, Ingrid E. Lundberg, Yeong‐Wook Song, Aziz Shaibani, Victoria P. Werth, Michael A. Maldonado   +5 more
wiley   +1 more source

Effects of oral administration of 5 immunosuppressive agents on activated T‐cell cytokine expression in healthy dogs

Journal of Veterinary Internal Medicine, 2020
Background Dogs are often adminstered >1 immunosuppressive medication when treating immune‐mediated diseases, and determining whether these different medications affect IL‐2 expression would be useful when performing pharmacodynamic monitoring during ...
Todd M. Archer, Charlee Mulligan, Lakshmi Narayanan, Caitlin Riggs, Claire Fellman, John M. Thomason, Robert W. Wills, Dawn M. Boothe, Crisanta Cruz‐Espindola, Roy Harmon, Andrew J. Mackin   +10 more
doaj   +1 more source

A Real-World Experience of Azathioprine Versus First-Line Disease-Modifying Therapy in Relapsing-Remitting Multiple Sclerosis—A Prospective Cohort Study

Brain Sciences, 2023
Azathioprine (AZA) has demonstrated efficacy in multiple randomized control trials (RCTs) for Relapsing-Remitting Multiple Sclerosis (RRMS). However, we still need comparative real-world data with other first-line disease-modifying therapies (DMTs).
Arpit Agrawal, M. V. Padma Srivastava, Rohit Bhatia, Vinay Goyal, Mamta Bhushan Singh, Venugopalan Y. Vishnu, Anuj Prabhakar   +6 more
doaj   +1 more source